CRMD Stock — CorMedix Inc.: Cash, EV, Pipeline

Share price

$7.72

Market cap

$601.7M

Cash

$256.7M

Enterprise value

$345.0M

Balance sheet

Cash	$256.7M
Debt	$0.0M
Net cash	$256.7M
Enterprise value	$345.0M
Basic shares	77.7M shares
Fully diluted shares	90.7M shares
Fully diluted market cap	$700.3M
Cash per share	$3.30

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CRMD daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 12 - Mar 25	(taurolidine and heparin) catheter lock solution	Phase 3	Central Line Associated Blood Stream Infections (CLABSI)	—
Aug 12 - Sep 23	(taurolidine and heparin) catheter lock solution	Phase 4	Catheter-Related Infections	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

DefenCath

Approved · Active

Indications

Hemodialysis (inpatient and outpatient settings) (Approved)

Status note Taurolidine and heparin; launched commercially in the U.S. in 2024. BARDA government contract in place (product not specified in excerpts).

REZZAYO

Approved · Active

Aliases rezafungin for injection

Partnerships Melinta Therapeutics: acquired by CorMedix Aug 29, 2025 ($453.7M); U.S. commercialization rights; Napp/Mundipharma: acquired global REZZAYO rights from Cidara (Apr 2024); $30-40M regulatory milestone on marketing approval for the prophylaxis indication

Indications

Candidemia and invasive candidiasis (adults) (Approved)
Prophylaxis of invasive fungal diseases in allogeneic BMT/HSCT (adults) (Phase 3)

Catalysts

— 2027

Status note Approved for candidemia and invasive candidiasis in adults. Positive Phase III topline from ReSPECT (prophylaxis of invasive fungal diseases in allogeneic BMT/HSCT) announced Apr 27, 2026; commercialization in the second indication targeted from 2027 if FDA-approved.

MINOCIN IV

Approved · Active

Indications

Acinetobacter infections (Approved)

Status note Acquired via Melinta; one of few agents approved for Acinetobacter species.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	(taurolidine and heparin) catheter lock solution
Lead indication	Catheter-Related Infections
Lead phase	Phase 4
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06714864	Phase 4	Recruiting	Sponsor	CorMedix Therapeutics	—	Catheter-Related Infections	—
NCT06822426	Phase 3	Recruiting	Sponsor	CorMedix Therapeutics	—	Central Line Associated Blood Stream Infections (CLABSI)	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for CorMedix Therapeutics on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

CRMD — CorMedix Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials